Patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab in the UK

被引：0
|
作者：
Peipert, J. Devin [1 ]
Griffin, M. [2 ]
Kulasekararaj, A. [3 ]
Yount, S. [1 ]
Martens, C. [4 ]
Sparling, A. [1 ]
Webster, K. A. [1 ]
Cella, D. [1 ]
Tomazos, I. [5 ]
Ogawa, M. [5 ]
Yu, J. [5 ]
Hill, A. [2 ]
Kaiser, K. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA
[2] St James Inst Oncol, Leeds, W Yorkshire, England
[3] Kings Coll Hosp London, Dept Haematol Med, NIHR Wellcome Kings Clin Res Facil, London, England
[4] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Alexion Pharmaceut Inc, Boston, MA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH2020-PO
引用
收藏
页码：143 / 144
页数：2
相关论文
共 50 条
  • [1] Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies
    Roeth, Alexander
    Rottinghaus, Scott T.
    Hill, Anita
    Bachman, Eric S.
    Kim, Jin Seok
    Schrezenmeier, Hubert
    Terriou, Louis
    Urbano-Ispizua, Alvaro
    Wells, Richard A.
    Jang, Jun Ho
    Kulasekararaj, Austin G.
    Szer, Jeff
    Aguzzi, Rasha
    Damokosh, Andrew I.
    Shafner, Lori
    Lee, Jong Wook
    [J]. BLOOD ADVANCES, 2018, 2 (17) : 2176 - 2185
  • [2] Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients
    Ishiyama, Ken
    Nakao, Shinji
    Usuki, Kensuke
    Yonemura, Yuji
    Ikezoe, Takayuki
    Uchiyama, Michihiro
    Mori, Yasuo
    Fukuda, Tetsuya
    Okada, Masaya
    Fujiwara, Shin-ichiro
    Noji, Hideyoshi
    Rottinghaus, Scott
    Aguzzi, Rasha
    Yokosawa, Jun
    Nishimura, Jun-Ichi
    Kanakura, Yuzuru
    Okamoto, Shinichiro
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (04) : 466 - 476
  • [3] Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients
    Ken Ishiyama
    Shinji Nakao
    Kensuke Usuki
    Yuji Yonemura
    Takayuki Ikezoe
    Michihiro Uchiyama
    Yasuo Mori
    Tetsuya Fukuda
    Masaya Okada
    Shin-ichiro Fujiwara
    Hideyoshi Noji
    Scott Rottinghaus
    Rasha Aguzzi
    Jun Yokosawa
    Jun-Ichi Nishimura
    Yuzuru Kanakura
    Shinichiro Okamoto
    [J]. International Journal of Hematology, 2020, 112 : 466 - 476
  • [4] Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two Phase 3 randomized, multicenter studies
    De Latour, R. Peffault
    Mitchell, L.
    Brodsky, R. A.
    Ortiz, S.
    Risitano, A. M.
    Jang, J. -H.
    Hillmen, P.
    Kulagin, A. D.
    Pradhan, R.
    Rottinghaus, S. T.
    Aguzzi, R.
    Wells, R. A.
    Szer, J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 110 - 110
  • [5] Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies
    De Latour, Regis Peffault
    Brodsky, Robert A.
    Ortiz, Stephan
    Risitano, Antonio M.
    Jang, Jun-Ho
    Hillmen, Peter
    Kulagin, Aleksandr
    Pradhan, Rajendra
    Rottinghaus, Scott T.
    Aguzzi, Rasha
    Wells, Richard A.
    Szer, Jeffrey
    [J]. BLOOD, 2018, 132
  • [6] Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab
    Kulasekararaj, Austin G.
    Hill, Anita
    Rottinghaus, Scott T.
    Langemeijer, Saskia
    Wells, Richard A.
    Gonzalez-Fernandez, F. Ataulfo
    Gaya, Anna
    Lee, Jong-Wook
    Gutierrez, Emilio Ojeda
    Piatek, Caroline I.
    Szer, Jeffrey
    Risitano, Antonio M.
    Nakao, Shinji
    Bachman, Eric
    Shafner, Lori
    Damokosh, Andrew I.
    Ortiz, Stephan
    Roeth, Alexander
    De latour, Regis Peffault
    [J]. BLOOD, 2018, 132
  • [7] A phase 3 study of Ravulizumab (ALXN1210) vs. Eculizumab in adults with paroxysmal nocturnal hemoglobinuria currently treated with Eculizumab: subgroup analysis by transfusion history and demographics
    Risitano, A.
    Roeth, A.
    Hill, A.
    Charbonnier, A.
    Schouten, H. C.
    Khaled, S.
    Gutierrez, E. O.
    Ogawa, M.
    Yu, J.
    Rottinghaus, S.
    Ishiyama, K.
    Kulasekararaj, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 302 - 302
  • [8] One-Year Efficacy of Ravulizumab (ALXN1210) in adult patients with paroxysmal Nocturnal hemoglobinuria naive to complement inhibitors
    Schrezenmeier, H.
    Kulasekararaj, A.
    Mitchell, L.
    de Fontbrune, Sicre F.
    Devos, T.
    Okamoto, S.
    Wells, R.
    Rottinghaus, S.
    Liu, P.
    Ortiz, S.
    Shafner, L.
    Lee, J. W.
    Socie, G.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 297 - 298
  • [9] One-year efficacy of ravulizumab (ALXN1210) in adult patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors
    Schrezenmeier, H.
    Gandhi, S.
    Kulasekararaj, A.
    Mitchell, L.
    de Fontbrune, F. Sicre
    Devos, T.
    Okamoto, S.
    Wells, R.
    Rottinghaus, S.
    Liu, P.
    Ortiz, S.
    Shafner, L.
    Lee, J. W.
    Socie, G.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 137 - 138
  • [10] Results from a phase 3, multicenter, noninferiority study of ravulizumab (ALXN1210) versus eculizumab (ECU) in adult patients (PTS) with paroxysmal nocturnal hemoglobinuria (PNH) naive to complement inhibitors (CI)
    Schrezenmeier, H.
    Lee, J. W.
    Rottinghaus, S. T.
    Lee, Lee L. W.
    Pessoa, V.
    Gualandro, S.
    Fuereder, W.
    Ptushkin, V.
    de Fontbrune, Sicre F.
    Volles, L.
    Shafner, L.
    Damokosh, A. I.
    Aguzzi, R.
    Pradhan, R.
    Ortiz, S.
    Hill, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 332 - +
12345